EGFR and non-small cell lung carcinoma: Osimertinib is the first Food and Drug Administration (FDA)-approved third-generation EGFR-TKIs, and has been used as the first-line therapy for advanced EGFR-mutant NSCLC, regardless of T790M mutation status (Soria et al. 2018).